Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators : An exploratory analysis of the PIONEER studies
© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd..
AIM: To assess how long participants with type 2 diabetes spent with HbA1c less than 7.0% and how likely they were to maintain this target with oral semaglutide 7 mg versus sitagliptin 100 mg or oral semaglutide 14 mg versus empagliflozin 25 mg, sitagliptin 100 mg or subcutaneous liraglutide 1.8 mg.
MATERIALS AND METHODS: Analyses used on-treatment data without rescue medication for all randomized participants (semaglutide [approved maintenance doses], n = 1880; comparators [not including placebo], n = 1412). Duration of time with HbA1c less than 7.0% was calculated using an HbA1c time curve. A binary endpoint of achieving HbA1c less than 7.0% at weeks 26 (week 24 for PIONEER 7) and 52 of each trial (and week 78 for PIONEER 3) was analysed.
RESULTS: Mean duration of time with HbA1c less than 7.0% was greater with oral semaglutide 7 mg versus sitagliptin in PIONEER 3 (27 vs. 22 weeks) and with oral semaglutide 14 mg versus empagliflozin and sitagliptin (27-34 vs. 19 vs. 22 weeks, respectively), and similar versus subcutaneous liraglutide. A greater proportion of participants achieved and maintained HbA1c less than 7.0% for more than 75% of the trial with oral semaglutide 14 mg versus oral comparators. The odds of achieving HbA1c less than 7.0% at weeks 24/26 and 52/78 were significantly greater with oral semaglutide 14 mg versus oral comparators or subcutaneous liraglutide, and with oral semaglutide 7 mg versus sitagliptin.
CONCLUSIONS: Oral semaglutide 7 and 14 mg resulted in greater time spent with HbA1c less than 7.0%, and a greater likelihood of achieving and maintaining HbA1c less than 7.0% versus oral comparators.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
---|---|
Enthalten in: |
Diabetes, obesity & metabolism - 26(2024), 2 vom: 08. Jan., Seite 532-539 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rosenstock, Julio [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 09.01.2024 Date Revised 09.01.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/dom.15339 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM364272244 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM364272244 | ||
003 | DE-627 | ||
005 | 20240114233014.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/dom.15339 |2 doi | |
028 | 5 | 2 | |a pubmed24n1253.xml |
035 | |a (DE-627)NLM364272244 | ||
035 | |a (NLM)37935463 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rosenstock, Julio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators |b An exploratory analysis of the PIONEER studies |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.01.2024 | ||
500 | |a Date Revised 09.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. | ||
520 | |a AIM: To assess how long participants with type 2 diabetes spent with HbA1c less than 7.0% and how likely they were to maintain this target with oral semaglutide 7 mg versus sitagliptin 100 mg or oral semaglutide 14 mg versus empagliflozin 25 mg, sitagliptin 100 mg or subcutaneous liraglutide 1.8 mg | ||
520 | |a MATERIALS AND METHODS: Analyses used on-treatment data without rescue medication for all randomized participants (semaglutide [approved maintenance doses], n = 1880; comparators [not including placebo], n = 1412). Duration of time with HbA1c less than 7.0% was calculated using an HbA1c time curve. A binary endpoint of achieving HbA1c less than 7.0% at weeks 26 (week 24 for PIONEER 7) and 52 of each trial (and week 78 for PIONEER 3) was analysed | ||
520 | |a RESULTS: Mean duration of time with HbA1c less than 7.0% was greater with oral semaglutide 7 mg versus sitagliptin in PIONEER 3 (27 vs. 22 weeks) and with oral semaglutide 14 mg versus empagliflozin and sitagliptin (27-34 vs. 19 vs. 22 weeks, respectively), and similar versus subcutaneous liraglutide. A greater proportion of participants achieved and maintained HbA1c less than 7.0% for more than 75% of the trial with oral semaglutide 14 mg versus oral comparators. The odds of achieving HbA1c less than 7.0% at weeks 24/26 and 52/78 were significantly greater with oral semaglutide 14 mg versus oral comparators or subcutaneous liraglutide, and with oral semaglutide 7 mg versus sitagliptin | ||
520 | |a CONCLUSIONS: Oral semaglutide 7 and 14 mg resulted in greater time spent with HbA1c less than 7.0%, and a greater likelihood of achieving and maintaining HbA1c less than 7.0% versus oral comparators | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a GLP-1 analogue | |
650 | 4 | |a antidiabetic drug | |
650 | 4 | |a glycaemic control | |
650 | 4 | |a incretin therapy | |
650 | 4 | |a semaglutide | |
650 | 4 | |a type 2 diabetes | |
650 | 7 | |a Hypoglycemic Agents |2 NLM | |
650 | 7 | |a empagliflozin |2 NLM | |
650 | 7 | |a HDC1R2M35U |2 NLM | |
650 | 7 | |a semaglutide |2 NLM | |
650 | 7 | |a 53AXN4NNHX |2 NLM | |
650 | 7 | |a Glycated Hemoglobin |2 NLM | |
650 | 7 | |a Liraglutide |2 NLM | |
650 | 7 | |a 839I73S42A |2 NLM | |
650 | 7 | |a Glucagon-Like Peptides |2 NLM | |
650 | 7 | |a 62340-29-8 |2 NLM | |
650 | 7 | |a Sitagliptin Phosphate |2 NLM | |
650 | 7 | |a TS63EW8X6F |2 NLM | |
700 | 1 | |a Cariou, Bertrand |e verfasserin |4 aut | |
700 | 1 | |a Eliasson, Johanna |e verfasserin |4 aut | |
700 | 1 | |a Frappin, Guillaume |e verfasserin |4 aut | |
700 | 1 | |a Kaltoft, Margit S |e verfasserin |4 aut | |
700 | 1 | |a Montanya, Eduard |e verfasserin |4 aut | |
700 | 1 | |a Knop, Filip K |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 26(2024), 2 vom: 08. Jan., Seite 532-539 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
773 | 1 | 8 | |g volume:26 |g year:2024 |g number:2 |g day:08 |g month:01 |g pages:532-539 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.15339 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 26 |j 2024 |e 2 |b 08 |c 01 |h 532-539 |